Prognostic impact of chronological age on efficacy of immune checkpoint inhibitors in non‐small‐cell lung cancer: Real‐world data from 86 173 patients

Immune checkpoint inhibitors (ICIs) have become standard pharmacological therapies in patients with non‐small‐cell lung cancer (NSCLC). Because elderly patients with NSCLC are often excluded from clinical trials as a result of lower functional capacity or comorbidities, the prognostic impact of chro...

Descripción completa

Detalles Bibliográficos
Autores principales: Takamori, Shinkichi, Shimokawa, Mototsugu, Komiya, Takefumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563149/
https://www.ncbi.nlm.nih.gov/pubmed/34612011
http://dx.doi.org/10.1111/1759-7714.14178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563149/
https://www.ncbi.nlm.nih.gov/pubmed/34612011
http://dx.doi.org/10.1111/1759-7714.14178

Ejemplares similares